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resumo 
 
 
O presente relatório descreve em detalhe as tarefas e atividades 
desenvolvidas no contexto de um estágio curricular durante o segundo ano do 
Mestrado em Biomedicina Farmacêutica, da Universidade de Aveiro. Este 
estágio teve lugar na Unidade de Farmacologia Clínica do Professor Joaquim 
Ferreira, do Instituto de Medicina Molecular, de 14 de setembro de 2015 a 27 
de junho de 2016. 
Esta experiência permitiu-me pôr em prática aquilo que aprendi no mestrado 
durante dez meses. Tive a oportunidade de trabalhar em três áreas diferentes 
da biomedicina farmacêutica: farmacovigilância, coordenação de ensaios 
clínicos e gestão de dados. 
Durante o estágio, surgiram múltiplas dificuldades e obstáculos. Contudo, 
consegui ultrapassá-los, melhorando as minhas capacidades profissionais, tais 
como organização, responsabilidade, comunicação, espírito critico, entre 
outras qualidades fundamentais para ser um bom profissional. 
Em conclusão, este estágio curricular permitiu o meu crescimento, não só 
como profissional, mas também como pessoa. Considero que tenha sido um 
desafio concretizado com sucesso e estou consciente que me abriu muitas 
janelas para a minha carreira futura. 
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This report describes in detail the tasks and activities developed in the 
context of a curricular internship during the second year of the Master’s 
degree in Pharmaceutical Medicine of the University of Aveiro. This internship 
took place in the Professor Joaquim Ferreira’s Clinical Pharmacology Unit 
(CPU) of the Instituto de Medicina Molecular, from September 14th, 2015 to 
June 27, 2016. 
This experience allowed me to put in practice what I learned from my 
master’s degree during ten months. I had the opportunity to work in three 
different areas of pharmaceutical medicine: pharmacovigilance, clinical trial 
coordination and data management. 
During the internship, several difficulties and obstacles showed up. 
However, I managed to surpass them, improving my professional skills, such 
as organization, responsibility, communication, critical thinking, among other 
fundamental qualities to be a good professional. 
In conclusion, this curricular internship allowed me to grow up, not only as a 
professional but also as a person. I think it was a successful challenge and I’m 
aware that it has opened many windows to future career. 
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1. Introduction 
This document is the final report of my curricular internship performed during the 
second year of the Master’s degree in Pharmaceutical Medicine of the University of 
Aveiro. It lasted 10 months, from September 14th, 2015 to June 27, 2016. The host 
institution was the Clinical Pharmacology Unit (CPU) of the Instituto de Medicina 
Molecular (IMM). 
The internship was divided in 3 subunits: 2 months in pharmacovigilance practice; 5 
months in clinical trials coordination and 3 months in data management. The aim was to 
learn and get experience in different areas instead of only one. It was an extended training 
of the real-world environment and a preparation to initiate my professional career.  
Before the beginning of the internship, I established some goals that I wanted to 
achieve. Maximum effort and spirit of sacrifice would be essential to accomplish them, in 
order to be better as a person and professional. Once I already had an idea of the 
subunits I would be working on, I committed to myself to accomplish the following 
objectives: 
 Develop my research and data management skills; 
 Improve my scientific writing skill; 
 Acquire qualification to be study coordinator and improve communication with 
patients; 
 Acquire qualification to work in pharmacovigilance and to get a better know-
how of the national adverse drug reaction notification system. 
 Improve my teamwork skill.  
 Acquire sufficient work versatility, to be prepared to try new professional 
experiences and challenges. 
This report is divided in 6 chapters. Apart from this first introductory chapter, the 
second one is an overview of the host institution, where I describe the structure of IMM 
and the main functions of the subunits of CPU. 
The third chapter is a set of the current knowledge about my main area of study – 
Clinical research and pharmaceutical development. Majorly based on bibliographical 
references, it is the background of the 3 subunits of my internship. 
The fourth chapter is where I describe the developed activities at each subunit. 
The skills learned, the difficulties experienced, the milestones overpassed and other 
relevant events are discussed in the fifth chapter. The conclusions of that discussion are 
presented in the last chapter. 
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2. Host Institution Overview 
2.1. Instituto de Medicina Molecular 
Instituto de Medicina Molecular (IMM) is a portuguese scientific institution focused on 
basic, clinical and translational biomedical research, in order to contribute to a better 
understanding of human diseases. Founded in December 2001, IMM is a private, non-
profit association and currently hosts approximately 400 researchers (1) and supports with 
scientific postgraduate training of young graduates, physicians and other health-care 
professionals. 
IMM has been improving its scientific productivity since its creation, reaching over 
4500 citations from publications of IMM researchers in 2013, who have published, in the 
same year, 89 papers (out of 305) in peer reviewed journals of impact higher than 5, and 
23 in journals of impact higher than 10 (2). 
Several IMM teams were recognized with national and international awards, including 
the Micahel J. Fox Innovation award, the Prémio Nacional de Inovação BES, the Pessoa 
award, the Crioestaminal award, amongst many others (2). 
IMM, Faculty of Medicine of Lisbon (FMUL) and Santa Maria University Hospital 
(HSM-CHLN) recently formed the Lisbon Academic Medical Centre – (CAML), a 
consortium aiming to promote the academic dimension in clinical practice, improve 
research development and innovation of medical education and health sciences. CAML 
renews the concept of an university hospital, ensuring the necessary compatibility of 
medical education with research and development of the health care mission (3). It has 
triggered the creation of start-up companies and several research collaborations on 
diverse areas of biomedical technologies, by facilitating the translation of research into 
clinical practice. 
The organisation of IMM is represented in figure 1. The blue shaded boxes represent 
the research unit where I did my curricular internship. 
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2.2. 
Figure 1 - Structure and Organization of Instituto de Medicina Molecular (Adapted from:  IMM 
Lisboa – Organização (1), available at https://goo.gl/d2bbuB). 
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Clinical Pharmacology Unit 
The CPU was created on 1st of July of 2013 and it is currently directed by Joaquim 
Ferreira, MD/PhD, clinical specialist and associate professor at School of Medicine of 
Lisbon. CPU has the mission to contribute to the development of effective and safe 
therapeutic interventions in neurological diseases, establishing optimized methodologies 
for the design, conduction, analysis and report of clinical trials (CT) (4). This unit also 
envision collaborations with pharmaceutical industries, leading to a better conduction of 
CTs, assuming a shared role in the early stages of clinical development (4). 
The activities of CPU are divided in sub-units, as shown in figure 2, and each one of 
them will be described in the next paragraphs. 
 
2.2.1. Regional Pharmacovigilance Unit 
CPU hosts a regional unit of the National Pharmacovigilance System (SNF) - Unidade 
de Farmacovigilância de Lisboa e Vale do Tejo (UFLVT).  
The National Pharmacovigilance System was created in 1992, to ensure the safety of 
commercialised medicines through the promotion and dissemination of safety control 
methods, especially in relation to spontaneous reports of Adverse Drug Reactions 
(ADRs). In the year 2000,  the SNF was decentralized in Regional Pharmacovigilance 
Units (URFs): North, Central, South, and Azores (5). Over the years, more Portuguese 
people have learned about the Pharmacovigilance System and its concept, so the 
numbers of spontaneous notifications (SN) of ADRs have been increasing. These high 
Figure 2 - Sub-units of the Clinical Pharmacology Unit – IMM 
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numbers of notifications lead to a restructuring of the URFs in 2013, and the former South 
Pharmacovigilance Unit became the current UFLVT, and a new South region unit was 
created with functions linked to the South Regional Health Administration (5). The 
INFARMED I.P, the Portuguese National Authority of Drugs and Health Products, hosts 
the SNP and became responsible for the reception of notifications from Madeira and 
Azores islands. Therefore, there are currently four URFs linked to University structures 
(5): 
 North Pharmacovigilance Unit (UFN) – School of Medicine of University of Porto.  
 Central region Pharmacovigilance Nucleus (NFC) – University of Coimbra. 
 Lisbon and Vale do Tejo Pharmacovigilance Unit (UFLVT) – School of Medicine of 
Lisbon. 
 South Pharmacovigilance Unit (UFS) – School of Pharmacy of University of 
Lisbon. 
Each URF has the function to receive, classify, process and validate spontaneous 
notifications with a minimum expected rate of 150 SN / million inhabitants / 1 year. UFLVT 
covers an area of about 3,6 million inhabitants. Other functions of the URFs are the 
communication to the Pharmacovigilance Department of INFARMED of SN and the 
promotion and dissemination of SNF and SN in the respective geographical areas (5). 
Further on this report I will describe my activities at UFLVT. 
2.2.2. Clinical Investigation Centre 
The Clinical Investigation Centre (CIC) is the CPU sub-unit responsible for CTs and 
Observational Studies (OS) conduction and coordination. It is physically located on the 6th 
floor of the Neurology Department of HSM-CHLN and holds a team of professionals, 
including neurologists, nurses, laboratory technicians, hospital pharmaceuticals and study 
coordinators, all contributing for a good and correct trial conduction. 
Neurological Diseases are the main focus of CIC. There are several ongoing CT for 
Movement Disorders and Dementia, such as Parkinson’s Disease (PD), Familial Amyloid 
Polyneuropathy (FAP), Huntington’s Disease (HD), Alzheimer’s Disease (AD), Multiple 
Sclerosis (MS), epilepsy and psychosis. It is an active centre in terms of patient recruiting 
and care, always looking forward to new CT and/or OS. 
CIC is the central point of communication between sponsors and health care 
professionals. Also, it is responsible for involving several departments of the hospital in 
the clinical studies, for better evaluation of patient tests and exams. For instance, some 
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professionals from the Cardiology department are involved in several CTs, being 
responsible for ECG trace evaluation, performing echocardiograms and other issues 
related to cardiovascular safety assessments. 
The hospital pharmacy has a clinical trial unit as well. It is responsible for receiving, 
preparing, manage and storage the study drugs and related materials. Therefore, the 
communication between the hospital pharmacy and CIC is constant and almost daily. 
They provide the study medication prescribed by CIC on study patient visits. All the study 
medication that patients bring to CIC return to the hospital pharmacy, either it is used, 
damaged, out of date or simply not taken. 
Working directly with CIC, there are study nurses responsible for drug infusions and 
blood samples collection, and a lab technician to process those samples.  
CIC also counts with clinical psychologists or “raters”, who evaluate patients with the 
gold-standard scales for neurological assessments, for example, C-SSRS (Columbia 
Suicide Severity Rating Scale), ADAS-cog (Alzheimer’s Disease Assessment Scale 
Cognitive Behaviour Section), HD-CAB (Huntington's Disease Cognitive Assessment 
Battery), among others. These rating scales are increasingly used as primary or 
secondary outcome measures in clinical studies in neurology (6). They are an important 
key upon which decisions are made that influence patient care and the adequacy of those 
decisions depends directly on their scientific quality (7). 
At last, but not the least, the Study Coordinators (SC) are the main role in CT 
management and all of the procedures involved. They have good understanding of the CT 
protocols, preparing each patient visit and communicating with all the personnel involved, 
to make sure that everything is done per protocol. Data collection is one of their main 
functions. There can be blinded and unblinded SC for the same studies, so unblinded SC 
work with more sensitive data, which blinded personnel cannot see. Study coordination 
was my role in CIC, during my internship. I will describe the activities I performed as a SC 
further in this document. 
2.2.3. Data Management 
This subunit is responsible for data treatment, biostatistics and medical writing. It 
focuses on data gathering and management of the lab’s several projects and studies. It 
has qualified employees that work with different types of databases (SQL, R, etc.) and do 
the statistical analysis. This work will result in interim analysis, to rectify the quality, safety 
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and integrity of the studies, and final reports and other important papers to be published in 
a later stage. 
Here I had the opportunity to perform database construction and a statistical analysis. I 
will describe them with more detail later on this report. 
2.2.4. Cochrane Review Group 
The Clinical Pharmacology Unit employs a representative of the Portuguese Branch of 
the Iberoamerican Cochrane Centre. The Cochrane Review Group consists in a global 
independent network of researchers, professional, patients, carers, and people interested 
in health. Around 130 countries work together, with contributions in the fields of medicine, 
health policy, research methodology, and consumer advocacy, to promote the development of 
systematic reviews and meta-analysis. 
Although I did some work related to systematic reviews, I had no direct contact with this 
subunit or developed activities for it. 
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3. State of the Art 
This chapter intends to contextualize my internship and the areas of pharmaceutical 
medicine I worked on, with the current state of clinical research and development. Also, it 
highlights the important aspects of drug development, since its discovery until it reaches 
market, the importance of data management during the clinical trial phase and the 
continuous safety evaluation, by pharmacovigilance. 
3.1. Clinical Research and Drug Development 
Clinical research is a subdivision of medical science that determines the safety and 
effectiveness of medications, devices, diagnostic products and treatment regimens for 
humans (8). Putting it simple, it involves human participants and helps translate basic 
research into new treatments and information to benefit patients (9). 
Different types of clinical research are used depending on what the researchers are 
studying (10). Prevention research aims to find better ways to prevent disorders from 
developing or returning. Types of prevention may vary, including new vaccines, or simply 
lifestyle changes. There is also diagnostic and screening research which looks for better 
ways to identify specific disorders and detect them in humans. Treatment research usually 
involves an intervention such as medication, psychotherapy, new medical devices, or new 
approaches to surgery. There are more types of clinical research, such as quality of life 
assessments, genetic studies and epidemiological studies that also contribute to a better 
clinical practice. 
Besides all these types of clinical research, usually they are all put together in two 
different groups: observational studies and interventional studies. Observational studies, 
also called epidemiological studies, are those where the investigator is not acting upon 
study participants, but instead observing natural relationships between factors and 
outcomes (11). Interventional study designs, also called experimental study designs, are 
those where the researcher intervenes at some point throughout the study (11).  
Clinical trials are interventional research studies that test how well new medical 
approaches, like new drugs, work in people. But for a new drug get to this point, it is 
necessary to go through a complex process of preclinical development first, right after its 
discovery. The rapid growth in scientific advances is enabling a greater understanding of 
diseases, but companies often focus their research and development where the science is 
 
 
Nuno Almeida  State of the Art 
 
  Curricular Internship in a Clinical Research Unit  9 
 
difficult and the failure risks are higher (12). On average, it takes between 10-12 years for 
a new medicine to go to the marketplace, since its discovery. CTs take, usually, 6 of those 
years to perform. The average cost to research and develop each successful drug is 
estimated to be €1.3 billion (figure 3). This value includes the cost of failures. The overall 
probability of clinical success, i. e., the likelihood that a drug entering clinical testing will 
eventually be approved is estimated to be less than 12% (12). 
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Figure 3 – Cost and Time of developing a new medicine. (Adapted from Cancer Research UK 
– “Dance with pharma” (33), available at: http://bit.ly/cruk-pharma ; and from GSK – “How 
we discover new medicines” (13), available at: http://bit.ly/2ep7Kbi  
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3.2. Drug Discovery and Preclinical Research 
The discovery process includes the early phases of research, which are designed to 
identify an investigational drug and perform initial tests. On this phase, researchers hope 
to identify a promising drug for further studies in laboratories and in animal models (12). 
Normally, researchers discover new drugs through new insights into a disease process, 
through tests of molecular compounds to find possible beneficial effects against any of a 
large number of diseases, through existing medicines on the market, but for a new 
therapeutic indication, or trough new technologies, such as those that provide new ways 
to target medical products to specific sites within the body or to manipulate genetic 
material (13). 
During this phase, thousands of compounds can be used, but only few will continue to 
further tests. Researchers will continue this process until they find a promising drug for 
development (13). Once it happens, researchers develop more experiments in order to 
gather information about its absorption, distribution, metabolization and excretion (ADME) 
properties, mechanisms of action, potential benefits, dosages and routes of 
administration, side effects, among other characteristics of the compound (13).  
With one or more compounds identified, researchers turn their attention to extensive 
testing in a preclinical phase. In this phase of research, scientists carry out both in vitro 
and in vivo tests, to determine if the lead compound is ready to be tested in humans. In 
vitro (“glass” in Latin) tests are experiments conducted in the laboratory, while in vivo 
(“life” in Latin) studies are those conducted in living cell and tissue cultures and animal 
models. 
Through this, researchers try to understand how the drug works and what potential 
side effects on humans might have (12), with detailed information on dosing and toxicity 
levels. Usually, it is not worth to perform extensive testing on the promising drug, because 
it might be spent too much money to get data that is not needed. What is really necessary 
is to guarantee whether the drug is safe and ready for human trials. 
3.3. Clinical Trials 
Clinical trials are research studies that test how well new medical approaches work in 
people (14). They look at new ways to prevent, detect, or treat disease. Treatments might 
consist in new drugs or combinations of drugs, new surgical procedures, devices, or new 
ways to use existing treatments (15). 
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CTs follow a specific study plan – the protocol. This document is developed by the 
researcher or manufacturer and is carefully designed to safeguard the participants’ health 
and answer specific research questions, such as (15) (16): 
 Who qualifies to participate (selection criteria); 
 How many people will be part of the study; 
 How long the study will last; 
 Whether there will be a control group and other ways to limit research bias; 
 How the drug will be given to patients and at what dosage; 
 What assessments will be conducted, when, and what data will be collected; 
 How the data will be reviewed and analysed; 
CTs are funded by various organizations or individuals, including physicians, 
foundations, medical institutions, voluntary groups, and pharmaceutical companies. These 
are called the sponsors (15). The sponsor is responsible for implementing and maintaining 
quality assurance and quality control systems with written standard operation procedures 
(SOPs) to ensure that trials are conducted and data are generated, documented, and 
reported in compliance with the protocol, good clinical practice (GCP), and the applicable 
regulatory requirements (17). 
Before the decision of participating in the study, participants must be given an 
informed consent – a document that provides the key facts about a clinical trial, such as 
its purpose, duration, required procedures, and who to contact for further information. The 
informed consent document also explains risks and potential benefits. The participant then 
decides whether to sign the document (15). The process of informed consent continues 
throughout the study. To help someone decide whether or not to participate, members of 
the research team explain the details of the study. Informed consent is not a contract. 
Volunteers are free to withdraw from the study completely or to refuse particular 
treatments or tests at any time (15). 
CT’s follow a typical series from early, small-scale, phase 1 studies to late-stage, large 
scale, phase 3 studies (16). 
3.3.1. Phase I 
In Phase I trials the candidate drug is tested in people for the first time. These studies 
are usually conducted with a small number of healthy volunteers, generally 100 or less. 
The main goal of a Phase I trial is to assess the safety of the medicine when used in 
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humans. Researchers look at the drug’s pharmacokinetics (what the organism does to the 
drug), and pharmacodynamics (what the drug does to the organism) (12).  
The typical phase I trial has a single ascending dose (SAD) design, meaning that 
subjects are dosed in small groups called cohorts. Each member of a cohort might receive 
a single dose of the study drug or a placebo. A very low dose is used for the first cohort. 
The dose is then escalated in the next cohort if it is safe to do so. Dose escalation is 
stopped when maximum tolerability and/or maximum exposure is reached (18). 
This phase lasts several months and only approximately 70% of drugs move to the 
next phase (16). 
3.3.2. Phase II 
Phase II trials are performed on larger groups (100 to 500 patient volunteers (12)) of 
patients and are designed to assess the efficacy of the drug and to continue the phase I 
safety assessments. Most importantly, phase II clinical studies help to establish 
therapeutic doses for the large-scale phase III studies (18). Phase II studies design 
depends on the compound's mechanism of action. Many patients receiving the drug are 
compared with patients receiving a different treatment, either placebo, or a different drug 
that is usually considered the standard of care for the disease (12). The length of this 
phase can be from several months to 2 years, and approximately 33% of drugs move to 
the next phase (16). 
3.3.3. Phase III 
Phase III trials generate statistically significant data about the safety, efficacy and the 
benefit-risk relationship of the investigational drug. Phase III trials may enrol 1,000 to 
5,000 patients across several clinical trial sites all over the world. This phase of research 
is essential to determine if the drug is safe and effective (18). These trials are the most 
expensive, time-consuming and difficult to design and run. Therefore, drugs that do not 
show promising results in phase II do not continue to phase III (12). Normally, a contract 
research organization (CRO) is contracted by the sponsor to manage and lead the 
company's trials, duties and functions (19). 
Phase III trials have an average duration between 1 to 4 years and only 25-30% of the 
drugs successfully end this phase with positive results and get authorized in market (16). 
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There is also a Phase IV, which consists in post-marketing trials involving safety 
surveillance (pharmacovigilance) and ongoing technical support after approval. Phase IV 
studies may be required by regulatory authorities or may be undertaken by the sponsoring 
company for competitive purposes or other reasons (18). 
3.3.4. Clinical data management 
Clinical data management is a critical phase in clinical research, which leads to 
generation of high-quality, reliable, and statistically sound data from clinical trials. The 
quality of this data has an important role in the study’s outcome. It consists in the process 
of collection and management of subject data in compliance with regulatory standards 
(20), including the Regulation (EC) No 45/2001, which seeks to protect the liberties and 
fundamental rights of individuals with respect to the processing of the personal data (21). 
Clinical data management includes several procedures such as: Case Report Form 
(CRF) designing, CRF annotation, database designing, data-entry, data validation, 
medical coding, data extraction, and database locking (20). 
Novel technology advances have allowed the developing of new and sophisticated 
tools, enabling clinical data management to handle large trials and ensure the data quality 
even in complex trials. This also helps to reduce drastically the time it takes from drug 
development to marketing (20). 
3.4. Pharmacovigilance and Drug Safety 
Once placed on the market, all medicinal products in the EU are subject to a strict 
testing and assessment of their quality, efficacy and safety before being authorised. They 
continue to be monitored so to assure that any aspect which could impact the safety 
profile of a medicine is detected and assessed and that necessary measures are taken. 
This monitoring is called pharmacovigilance (22). 
Pharmacovigilance has been defined by the World Health Organization (WHO) as “the 
science and activities relating to the detection, assessment, understanding and prevention 
of adverse effects or any other medicine-related problem” (23). The main objectives of 
pharmacovigilance include prevention of harm from adverse reactions in humans and 
promotion of the safe and effective use of medicinal products (23). 
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The initial idea and concept of pharmacovigilance came with the WHO Programme for 
International Drug Monitoring in 1968, in response to the thalidomide disaster in the 
1960s, where about 10,000 babies were born with deformities as a result of the adverse 
effects of thalidomide (24).  
The current need of pharmacovigilance is due to the limited amount of information 
available from CTs. Patients in CTs are selected carefully and followed up very closely 
under controlled conditions. However, after marketing authorization (MA), patients using a 
medicine may have other diseases and may be taking other medicines. It will also be used 
in a larger number of patients, increasing the possibility of rare side effects being 
discovered. Some side effects may only start to emerge once a medicine has been used 
for a long time (25). 
The good pharmacovigilance practice (GVP) provides guidance on the conduct of 
pharmacovigilance for specific product types or specific populations in which medicines 
are used (23). These practices are designed to efficiently and effectively detect and alert 
the drug safety professional to new and potentially important information on drug-
associated adverse reactions (26). GVP apply to marketing-authorisation holders, the 
European Medicines Agency and medicines regulatory authorities in EU Member States 
(25). 
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4. On-the-Job Training 
4.1. Activities Developed in Pharmacovigilance 
The assessment of quality, efficacy and safety of medicines does not end after MA. 
Any aspect which could impact their safety profile is detected and assessed by continued 
monitoring through pharmacovigilance (22). 
Before MA, clinical trials, if performed strictly and correctly, provide sufficient 
information about safety and efficacy of the drug for its approval. However, in most of the 
cases, the target population is far greater than the tested sample. So, the real-world safety 
and efficacy must be continuing monitored because there could be several drug effects 
yet to be discovered and assessed. Not only adverse events, but also harmless 
secondary effects or even new therapeutic indications. 
As I mentioned before on this report, the UFLVT function is to receive, classify, 
process and validate spontaneous notifications of ADRs. On my first week, I read about 
ADRs and the pharmacovigilance unit. The Management Quality Plan was essential to 
understand the dynamics and procedures in a systemized way.  Also, I read European 
guidelines, including the EMA guideline on GVP. The GVP guideline is divided in several 
modules and aims to facilitate the performance of pharmacovigilance in the European 
Union, covering medicines authorised centrally via the Agency as well as medicines 
authorised at national level (27). 
On the weeks after that, I was assigned to validate spontaneous notifications of ADRs 
that are sent to UFLVT via e-mail, letter, phone or fax. A validated notification has the 
minimum information required to be processed (28): 
 Adverse reaction description; 
 Identification of the medicine suspected to have caused the adverse reaction; 
 Information of the person who experienced the adverse reaction; 
 Contact details of the reporter of the adverse reaction. 
When some of these were missing, the reporter would be contacted in order to provide 
core information and other details about the case. 
During validation, it is crucial to identify whether the reported ADR is a Serious 
Adverse Event (SAE). An adverse event is any undesirable experience associated with 
the use of a medical product in a patient (29). The event is serious when occurs one of the 
following outcomes: death; life-threatening; hospitalization (initial or prolonged); disabilities 
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or permanent damage; congenital anomaly/birth defect; required intervention to prevent 
permanent damage; or other serious important medical events (IME) (29). A list of IMEs 
released by EMA is available for consulting. The responsible physician can consider 
whether it is a SAE, after appropriate medical judgement, even if it does not fit in any of 
the outcome stated above. If the reported patient experienced a SAE, then it must be 
reported to INFARMED within 24 hours. 
After validation, I inserted the notification’s information on INFARMED’s online tool for 
ADRs reporting: Portal RAM. While I was doing this, one of the obstacles was the 
translation of the ADR description, sometimes written in popular language, to a scientific 
and standardized designation. MedDRA dictionary was the ideal tool for this task, since 
the online portal accepted ADR inputs in MedDRA language only. MedDRA stands for 
“Medical Dictionary for Regulatory Activities” which is a rich and highly specific 
standardised medical terminology to facilitate sharing of regulatory information 
internationally for medical products used by humans (30). It was developed under the 
auspices of the International Conference on Harmonisation (ICH) of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (30). When all 
information was successfully submitted to Portal RAM, the notification would be in standby 
until the reporter was contacted for further information and to know the current state of the 
ADR (persisting, improving, or cured). This is preferably done by phone call in a maximum 
of 7 days after the reception of the notification. 
Another of my activities was to elaborate narratives of the notifications, i. e., to write a 
text with all the relevant information of the case, starting with the identification of the 
patient, the SAE(s) experienced, the suspected medicine (start and finish dates; dosage), 
concomitant medication, medical history, etc. This is one of the final fields to fill in the 
Portal RAM. 
In the end, all notifications are sent to the physician responsible for the causality 
attribution. He, after medical judgment, will attribute the relation between the suspected 
medicine and the ADR as unlikely, possible, probable, certain, not related or not 
assessable. Then a causality report is generated and sent to INFARMED and to the 
reporter. 
Until the case is considered closed, UFLVT will stay in contact with the reporter to 
keep him updated with the decisions made about the case and to assess the evolution of 
the ADR. 
During the time I was in UFLVT I have learned quite much about pharmacovigilance 
practice. I even had the opportunity to participate in a 4-day intensive course of 
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Pharmacovigilance, developed by UFLTV personnel. At the end of the internship, I 
considered myself capable of doing some of the activities autonomously.  
4.2. Training in Coordination of Clinical Trials 
When I began the internship in coordination of clinical trials, the studies were divided 
and assigned to me and to my colleagues. My main function as a SC was to coordinate 
the few studies assigned to me. My colleagues’ studies were not my responsibility. 
Although, when help was needed and, effectively, it could be given without neglect other 
studies, it would be valued. 
CIC, that hosted me during five months, works only with neurology studies. The CTs 
that I helped to coordinate allowed me to have contact with three neurological diseases: 
Parkinson disease (PD), Huntington disease (HD) and familial amyloid polyneuropathy 
(FAP). 
First, I had to read the protocols of all my studies to understand their nature, their 
methods, the documentation, materials and everything that was indispensable to prepare 
the visits of the participants to the centre, and the whole scheduling of the study. Most of 
the times, there was a pocket protocol provided by the sponsor, for consulting anywhere 
and anytime to answer some last minute questions. 
One of the most important tasks was to prepare study visits. In every study protocol, 
there was a systemized schedule of all the participant’s visits. There, it was possible to 
retrieve all the information needed for that visit: which variables would be measured to the 
patient, questionnaires, analysis and exams, what would be analysed in the blood 
samples and how to process them and get them ready to send to the central laboratory. 
Therefore, in the days before the visit day, I would check all this information and prepare 
the visit. I gathered all documentation needed (visit checklists, questionnaires, etc.) from 
the source files, and the blood/urine sample collection kit(s) necessary for that visit. 
Usually, these kits were identified and organized by visit. They contained, mostly, 
collection tubes, for blood collection by a phlebotomist, and the transfer tubes, the ones to 
be sent to the central with the blood serum, obtained by centrifugation.  In some studies, 
collection and transfer tubes came already labelled, while in others I had to do that 
manually with the labels provided separately. 
In addition, every personnel involved in that visit would be contacted and informed of 
their tasks for that day. Patients would be contacted as well, in order to remind the hour 
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and date of the visit and of special care needed or medication, documents, etc. that they 
had to bring with them to the centre. 
When a visit included treatment with the test drug, it had to be requested to the 
hospital’s pharmacy, to pharmacists adequately trained for that CT, by Interactive Voice 
Response System (IVRS) or by Interactive Web Response System (IWRS). The first 
consists in a phone call to an automated system where, with the patient ID, visit number, a 
secret password and other relevant information (depending on the study), it was possible 
to prescribe medication to that patient. The second one is by a website, essentially with 
the same methods. 
Thereby, with all the elements needed and all people informed, the visit would occur 
more fluidly, with less time waste. The efficiency of a visit was directly dependent of its 
good preparation. 
On days with patients’ visits, mostly my function was to accompany them to the right 
places, fill the checklists with the information as soon as I got it, such as weight, blood 
pressure, temperature, etc. and the time they were measured, and to process the blood 
and urine samples. Every study had a laboratory guide with instructions for all samples on 
how to process them: clotting time after collection, speed and temperature of the 
centrifuge, quantity needed for the transfer tubes, shipping method (ambient or dry ice) 
and storage conditions. 
Besides patient visits, I had another important function in back office: CRFs data input 
and query resolution. A CRF is a specialized document in clinical research, designed to 
collect the patient data in a clinical trial (31). Although paper CRFs are still used largely 
around the globe, most of the centre’s studies used electronic case report forms (eCRFs). 
They are properly designed to receive all necessary data demanded by protocol. It is a 
dynamic file that requires constant updates and monitoring. The eCRFs have the 
advantage of being programmed to be sensitive about the information inserted in the 
system. Despite the personnel responsible for monitoring these CRFs, the system itself 
generates automatic queries if data is not inserted by the predetermined standards. When 
these and other queries showed up in the eCRF, I had to solve them, by correcting 
transcription errors, consulting source files, etc. depending on the nature of the query. 
All CTs had scheduled monitoring visits by the clinical research associate (CTA). 
Before that day, I prepared and organized every documentation, patient files and other 
relevant details to facilitate the monitoring process. In that day, the CTA was responsible 
to ensure the high quality of data and to check if there were any protocol deviations and 
mark them for resolution. Also, it was a good time for answering any questions about the 
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study, to discuss the best way to perform some tasks and to give an overview about the 
current situation of the study. 
These were my activities developed at the CIC, from which I learned much. Also, I 
developed skills that I think to be essential for every professional, especially in healthcare 
and clinical investigation areas. 
4.3. Activities Developed in Data Management 
The last stage of my internship was a data management experience. Actually, my 
activities here were not as many as I initially expected, but it doesn’t mean that I didn’t 
learn with it. 
My major activity was to organize a database and fill any missing information. This 
was a database of four clinical studies, each one with few hundreds of patients (between 
100 and 300). My job was to check the common variables among all studies and to 
retrieve that information from raw data to an organized excel file. It took some time to 
complete this task, because of the standardization of every variable. For example: 
transform variables with “sim / não”; “y / n”; etc. into a standard format, like “Yes / No”; or 
make the conversion of values of the same variable to the same unit of measurement. 
The aim of this database was a complete statistical analysis of all studies. This 
evaluation used advanced statistical methods that I never used and wasn’t comfortable 
with. Thereby, my task was only to finalize the database. The statistical evaluation would 
be performed by my superior in data management. 
Nevertheless, the other task assigned to me was a descriptive statistical analysis. This 
one wasn’t so time consuming. It consisted in calculate means, medians, confidence 
intervals at 95% (CI=95%), minimums and maximums of several variables, such as 
weight, age, and the other study specific measures at three different stages of the 
treatment. To do this, I used the SPSS tool to analyse the database given to me. I 
performed the data selection and then, with knowledge acquired from the master’s 
statistics module, worked with SPSS to make a descriptive statistical analysis. After 
obtaining the results, I created a slideshow so I could display those results in an organized 
and easy way to understand. 
This last task was part of an interim analysis of a study. An interim analysis is an 
evaluation of the current data from an ongoing trial, in which the primary research 
question is addressed, and which has the potential for modifying the conduct of the study 
(32). With this activity, I was able to take the first steps of an interim analysis. 
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Although I performed only few activities at data management internship, they were 
very valuable and instructive tasks. 
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5. Discussion 
This chapter is an overview of the impact that this internship had in my life, at all 
levels. I intend to demonstrate what I knew at the start of it and how I grew up and 
learned, to be the person with much more knowledge that I am today. In other words, this 
chapter highlights the reason of this internship and the importance of it. 
The internship at the CPU was indeed a changing experience. The idea of a first real-
world work experience can be frightening at the beginning, but it is rewarding at the end. 
Ten months of activities developed with a multifaceted team did make a difference in my 
evolving process, not only as a person but as a professional too. The environment was 
ideal to learn and improve work skills, but difficulties and obstacles appeared when least 
expected and things tended to get complicated sometimes. For me, the real challenge of 
this internship was to surpass those obstacles and solve imminent problems that are not 
in the books. 
At the pharmacovigilance unit, the challenge was the unexpected number of 
notifications that we could receive in only one day. Each notification requires a whole 
process, as I described early on this report. The dynamic of the unit is consistently fluid 
and well structured, so, usually, the notification processing occurs normally without any 
delays. Although, in some days, the quantity of notifications sent to the unit is higher than 
normal, increasing workload significantly. The challenge here was to do the same things 
I’ve progressively learned to do, but with the pressure of doing it faster with the same 
quality of work. On the first times, I had some difficulties to conciliate everything, including 
the pressure, but in the end, I had my performance improved with very few difficulties. 
In my opinion, increase of workload happens in every work environment, so I was 
satisfied with my evolution and quick adaptation to this first obstacle. This skill was very 
important since, after the pharmacology unit, I went to CIC, to coordinate CTs, where the 
workload is much more unstable. 
The things I’ve learned from the pharmacovigilance internship were very interesting 
and quite surprising. There, I had the opportunity to integrate in a real system of constant 
evaluation and control of medicines. I was encouraged to read and to learn in every step 
of my training. I would like to participate in an auditing preparation process but I didn’t 
have the opportunity to do so, because I started the internship few weeks after an auditing 
by INFARMED. It was an exceptional experience and the welcome was very pleasant. In 
the end, I was treated like another professional and it really felt that I was part of this 
team. 
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The training at CIC was quite more challenging. Half of my curricular internship (five 
months) was spent as SC, so there was enough time to encounter all types of obstacles. 
Most of the activities developed in this centre are dependant of more than one person, so 
it was easy for something to go wrong. This was my first milestone here: to take fully 
control of my tasks in order to guarantee that everyone is informed and the right 
information is given, so that misunderstandings could be avoided. It seems easy, but 
when many tasks are pending, it’s difficult keep track on everything. 
At the beginning of CIC training, I had guidance by my co-workers, so I could get used 
to the centre’s dynamics. This was crucial to perform my activities correctly and in the 
right time. I learned that scheduling all CIC’s events was imperative, in order to keep 
everything organized with antecedence. The reason of this is because unexpected 
situations occur all the time and, when it happens, it is good to have the expected ones 
under control. 
The unexpected is indeed a keyword in clinical trial coordination. Even when 
everything is well prepared and anticipated, there can always be occasions beyond our 
control, for example, patients arriving late to the centre, delaying all procedures with 
different professionals (physicians, nurses, psychologists, etc.) that have tight schedules 
and other commitments; or when it is impossible to collect blood samples, for some 
reason, and it is necessary to reschedule another day to do it, without violating the 
timelines established by protocol. These are situations that need quick solutions. Fast 
thinking is required to take immediate actions to solve the problem, avoiding further 
complications. It is the most important quality of any SC and I am very proud to say that I 
managed to learn it, almost instinctively, during the five months. In my opinion, the will to 
adapt is fundamental in a professional experience like this and I think I adapted quite 
rapidly to this new way of working. 
  Another crucial point of my training as a SC was the responsibility that the job 
implies. It was not an obstacle or an evident difficulty, but I had to be aware that I was 
dealing with people, most precisely, with patients that need care and special attention. So, 
the consequences of possible mistakes and negligent acts would be severe and could 
result in negative impacts in patients’ participation in the study. Therefore, I had to think 
and to act as a healthcare professional, i. e., I’ve managed to perform every task and 
activity, keeping in mind what decisions would be more convenient for patients’ life, for 
example, when a patient had to go through many exams and evaluations, I tried to 
schedule everything to one single day, if possible, to avoid multiple visits to the hospital, 
which would be tiring to the patient and would compromise his professional life, if that was 
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the case. Even if that meant a little more sacrifice of our part. This was the first time during 
my internship that I felt I had fully responsibility of my actions, even though with a little 
guidance, unlike the pharmacovigilance training, where everything I did had supervision 
before its submission. I learned much with this type of responsibility. It helped me grow as 
a human being, giving priority to more important values. 
Despite all obstacles and difficulties, working as a SC allowed me to have very positive 
experiences. Contact with patients was one of them. It was challenging but fascinating at 
the same time. All patients had their own peculiarity and I had to adapt my speech and 
behaviour for each one. It was difficult in the beginning but, with time, I gradually improved 
my communication skill. Actually, it was the best part of my whole internship, because I 
had the opportunity to have direct contact with the main reason this area of study exists: 
patients. It is for them that pharmaceutical research and development is made and it’s 
because of them that I am so interested in it. Clearly, I knew this all along, but it was when 
I sit in front of a real patient, with a real disease that this became even clearer. 
I would say that these five months working as a SC had a meaningful impact in my 
learning process. In the beginning, I interrupted many of my tasks to read and to ask 
questions, and I had some difficulties to communicate with patients. Also, everything 
seemed to happen at the same time and all seemed impossible to conciliate. I improved 
much in each day and I’m aware that, in the end, I was a better professional, performing 
my tasks fluidly, anticipating every event and communicating with patients with more 
confidence. These were the good things I took from this experience. 
The next and final stage of my internship was not so challenging. Working in data 
management was a more pacific experience, compared to the previous one. Here, I had 
more time to think about the best way to perform the tasks I described earlier on this 
report, to search more information and to take a look at other databases and statistical 
analysis. It was exactly the opposite of the CIC’s training: while there I had to think fast 
and take quick decisions, in data management, every decision was timely considered as 
well as every detail, in order to guarantee the quality of the work. 
Constructing a database was a long and time consuming task but very interesting too. 
I’ve managed to elaborate tools to help me organize several data entries. This helped me 
improving my organizational skills. A well elaborated database facilitates its analysis and it 
is easier to consult, and that is what I tried to do. Also, I understood why activities like this 
take time and need concentration to perform. 
The second task, where I had to perform a descriptive statistical analysis, also helped 
me to understand the importance of biostatistics in this area. I did this activity resorting to 
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what I learned from one of my master’s module. As I described earlier, this was a basic 
task and it was not necessary to use advanced methods. Finishing the analysis was 
relatively easy. The challenging part was presenting the results. Creating a slideshow 
seemed a simple task, but it is necessary taking into account what is important to present 
and how to display those results in that presentation. At the first try, I simply pasted the 
results in as they were displayed by SPSS. But then I was told that the way we present 
the statistical results is very important. It is not enough to show the obtained data. In a 
presentation, it is crucial being able to show what it means and how it answers the study’s 
questions. My skill in statistics did not improve substantially with this task, but it was good 
to test my knowledge in the area by doing it alone without any help. The main lesson here 
was the importance of it, when we intend to assess the quality of a study. If the results are 
negative, it is possible to end the study earlier than scheduled. 
In overall, I can say that I was able to surpass almost every obstacle and difficulty. In 
addition, I could retrieve lessons from them and learn something important and useful for 
my future. 
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6. Conclusion 
On the second year of my master’s degree, I performed a 10-month curricular 
internship at the CPU. This report intends to illustrate that experience, to discuss what I 
learned from it and how I grew up as a future professional. 
It was a unique internship because I had the opportunity to work in three areas of 
pharmaceutical medicine and experience different ways to embrace the problems and 
how to solve them. During the 10 months, I faced many challenges and obstacles. 
However, each one of them allowed me to improve my professional skills, such as 
organization, responsibility, communication, critical thinking, scheduling and working 
under pressure. These skills are what I treasure from the most difficult parts of the job. 
Working on pharmacovigilance allowed me to understand the importance of the 
continuous evaluation of medicines to assure their safety. Also, I understand that 
everyone has an important role in this process, by reporting adverse events, contributing 
to clinical research. At CIC, I managed to comprehend the responsibilities of a SC and the 
importance of this role on the success of CTs. Not only because of the tasks they perform, 
but also the problems they solve and the complications they avoid. The contact with 
patients was one of the best experiences as a SC and a wonderful mark in my life. In data 
management training, I understood the importance of the back-office tasks and how it is 
crucial to have this side of clinical research constantly working and publishing data, from 
which will be possible to take conclusion and continue to improve pharmaceutical 
research and development. 
These 10 months were a period of constant learning and growth. Compared to what I 
was and what I had before this internship, today I am a person who evolved in all levels, 
being more capable of developing new activities and accepting more challenges. 
Everything I went through during this internship and what I learned from it was an 
exceptional way to complete my master’s degree and to consolidate a whole year of 
training and formation. I would classify this internship as a positive mark in my learning 
process and a good starting point for my future career. I am conscious that the opportunity 
of working in a prestigious unit like CPU potentially opened many windows to begin a solid 
career. Now, it is my turn to avail the good things I took from the internship and look for 
other opportunities, in order to continue to grow and improve this professional journey, 
which began with this curricular internship. 
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